Purpose: Although adjuvant chemotherapy reduces the risk of disease recurrence in stage III colon cancer patients, published guidelines do not specify when it should be initiated. This study aimed to assess the effect of adjuvant chemotherapy initiation time on disease recurrence and survival in stage III colon cancer patients undergoing curative surgical resection.
Methods: The medical records of stage III colon cancer patients undergoing curative resection between February 2004 and December 2009 were reviewed.
Results: Of the 133 enrolled patients, 27 (20.3%) began adjuvant chemotherapy within 3 weeks of surgery, whereas 106 (79.7%) did after 3 weeks following surgery. Patients receiving chemotherapy within 3 weeks of surgery were less likely to experience recurrences than those beginning treatment later (11.1% vs. 33%, P = 0.018). The mean disease-free survival of patients receiving adjuvant therapy earlier was 54.6 months, whereas that of patients with later treatment was 43.5 months (P = 0.014). However, no significant differences in overall survival were observed between the 2 groups.
Conclusion: Adjuvant chemotherapy should be initiated as soon as a patient's clinical condition allows. Patients with stage III colon cancer may benefit from adjuvant chemotherapy initiated within 3 weeks of surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559614 | PMC |
| http://dx.doi.org/10.4174/astr.2015.89.3.124 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global prevalence and moderating factors of malnutrition in colorectal cancer survivors: A meta-analysis.
J Cancer Surviv
January 2025
School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
Purpose: This meta-analysis aims to estimate the global prevalence of severe, moderate, overall malnutrition and moderating factors of malnutrition in colorectal cancer (CRC) survivors.
Methods: A comprehensive search was conducted in Embase, CINAHL, Medline-OVID, PubMed, Scopus, and Web of Science from inception to February 8, 2024, without language, region, or publication date restrictions. A generalized linear mixed model and random-effects model were used to examine the pooled prevalence, and moderator analyses were implemented to investigate variations in the pooled prevalence.
Feasibility and safety of hyperthermic intra-peritoneal chemotherapy in patients with ovarian cancer and chronic kidney disease.
Int J Gynecol Cancer
January 2025
Division of Gynecologic Oncology, Obstetrics & Gynecology Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Objective: This study aimed to compare perioperative outcomes and progression-free and overall survival in patients with chronic kidney disease (CKD) versus those without after hyperthermic intra-peritoneal chemotherapy (HIPEC) for ovarian cancer.
Methods: This is a retrospective, single-institution cohort study of patients with ovarian cancer treated with HIPEC at the Cleveland Clinic from January 2009 to December 2022. All patients received HIPEC with cisplatin and renal protection with mannitol and furosemide.
The Impact of Chemotherapy on the Nutritional Status of Breast Cancer Patients.
Cureus
December 2024
Institute of Biochemistry and Biotechnology, University of Veterinary and Animal Sciences, Lahore, PAK.
Background: Breast cancer is one of the most common cancers among Pakistani women. It is mostly diagnosed at stage 2, requiring chemotherapy in certain cases. Chemotherapy is of two types: adjuvant and neoadjuvant.
View Article and Find Full Text PDFA Rare Case of Juvenile Granulosa Cell Tumor in a Premenarchal Female: Clinical Presentation, Diagnosis, and Management.
Cureus
December 2024
2nd Pediatric Surgery Department, Athens Children's Hospital P&A Kyriakou, Athens, GRC.
Juvenile granulosa cell tumors (JGCTs), a rare type of ovarian tumor, are predominantly seen in premenarchal girls. We report a case of a 4.5-year-old girl with precocious puberty and a left ovarian JGCT, confirmed through imaging and histopathology.
View Article and Find Full Text PDFDifficulties in the diagnosis and treatment of axillary malignant triton tumors: A case report.
Oncol Lett
March 2025
Department of Oncology, The Liuzhou Worker's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region 545005, P.R. China.
Malignant triton tumor (MTT), a subtype of malignant peripheral nerve sheath tumor, is a rare soft-tissue sarcoma with a difficult diagnosis and poor prognosis. The course of MTT progression is rapid and the degree of malignancy is high. Patients with MTT can be treated with postoperative adjuvant radiotherapy and chemotherapy; however, treatment results are still poor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!